Should I buy or sell Amarin stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" AMRN shares. View AMRN analyst ratings or view top-rated stocks .

What is Amarin's stock price target for 2024?

3 analysts have issued 1-year price objectives for Amarin's shares. Their AMRN share price targets range from $1.00 to $1.25. On average, they predict the company's stock price to reach $1.08 in the next year. This suggests a possible upside of 44.4% from the stock's current price. View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts .

How have AMRN shares performed in 2023?

Amarin's stock was trading at $1.21 at the beginning of 2023. Since then, AMRN shares have decreased by 38.0% and is now trading at $0.75. View the best growth stocks for 2023 here .

When is Amarin's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our AMRN earnings forecast .

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) issued its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The biopharmaceutical company earned $66.06 million during the quarter, compared to analysts' expectations of $57.56 million. Amarin had a negative net margin of 16.27% and a negative trailing twelve-month return on equity of 9.12%.

What is John Thero's approval rating as Amarin's CEO?

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com . John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU) , Advanced Micro Devices (AMD) , NVIDIA (NVDA) , Block (SQ) , Alibaba Group (BABA) , Tesla (TSLA) , Bank of America (BAC) , Netflix (NFLX) and Novavax (NVAX) .

Who are Amarin's major shareholders?

Amarin's stock is owned by many different institutional and retail investors. Top institutional shareholders include Kynam Capital Management LP (2.98%), SCP Investment LP (0.74%), Stadium Capital Management LLC (0.47%), 13D Management LLC (0.37%), Axxcess Wealth Management LLC (0.32%) and UBS Group AG (0.19%). Insiders that own company stock include David M Stack , Joseph S Zakrzewski , Michael Wayne Kalb , Olsen Per Wold, Patrick Holt and Steven B Ketchum . View institutional ownership trends .

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Amarin have any subsidiaries?

The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited. Read More

Amarin Stock Price, News & Analysis (NASDAQ:AMRN)

$0.75

+0.01 (+1.35%)

(As of 11/29/2023 ET)

Compare

Today's Range: $0.73
▼
$0.76
50-Day Range: $0.66
▼
$0.95
52-Week Range: $0.65
▼
$2.23

Volume: 919,825 shs
Average Volume: 1.26 million shs
Market Capitalization: $302.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.08

Amarin MarketRank™ Stock Analysis

Analyst Rating: Sell
1.33 Rating Score
Upside/Downside: 44.4% Upside
$1.08 Price Target
Short Interest: Healthy
3.79% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.18) to ($0.19) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

777th out of 949 stocks

Pharmaceutical Preparations Industry

368th out of 432 stocks

2.7

Analyst's Opinion

Consensus Rating
Amarin has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no buy ratings, 1 hold rating, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.08, Amarin has a forecasted upside of 44.4% from its current price of $0.75.
Amount of Analyst Coverage
Amarin has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.79% of the outstanding shares of Amarin have been sold short.
Short Interest Ratio / Days to Cover
Amarin has a short interest ratio ("days to cover") of 9.8.
Change versus previous month
Short interest in Amarin has recently decreased by 3.59%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Amarin does not currently pay a dividend.
Dividend Growth
Amarin does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMRN.

3.8

News and Social Media Coverage

News Sentiment
Amarin has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Amarin this week, compared to 2 articles on an average week.
Search Interest
9 people have searched for AMRN on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.
MarketBeat Follows
3 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amarin insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.81% of the stock of Amarin is held by insiders.
Percentage Held by Institutions
Only 25.51% of the stock of Amarin is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Amarin are expected to decrease in the coming year, from ($0.18) to ($0.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amarin is -5.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amarin is -5.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Amarin has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Amarin Stock (NASDAQ:AMRN)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AMRN Stock News Headlines

November 21, 2023 | americanbankingnews.com

Amarin (NASDAQ:AMRN) Receives Underweight Rating from JPMorgan Chase & Co.

November 2, 2023 | finance.yahoo.com

Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript

November 30, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

November 2, 2023 | finance.yahoo.com

Are Investors Undervaluing Amarin Corporation plc (NASDAQ:AMRN) By 27%?

November 1, 2023 | finance.yahoo.com

Amarin Corp PLC (AMRN) Reports Q3 2023 Earnings: Net Revenues Down 27% Year-Over-Year

November 1, 2023 | finance.yahoo.com

Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

November 1, 2023 | finance.yahoo.com

Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript

November 1, 2023 | finance.yahoo.com

Amarin Reports Third Quarter 2023 Financial Results

November 30, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

November 1, 2023 | sfgate.com

Amarin: Q3 Earnings Snapshot

November 1, 2023 | morningstar.com

Amarin Corp PLC ADR AMRN

October 31, 2023 | finance.yahoo.com

Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

October 26, 2023 | msn.com

Jefferies downgrades Amarin to 'hold'; shares down

October 26, 2023 | finance.yahoo.com

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

October 19, 2023 | finance.yahoo.com

Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

September 20, 2023 | finance.yahoo.com

Amarin (NASDAQ:AMRN) Is In A Good Position To Deliver On Growth Plans

September 12, 2023 | finance.yahoo.com

Amarin to Present at the 2023 Cantor Global Healthcare Conference

August 31, 2023 | msn.com

Amarin Corp - ADR (AMRN) Price Target Increased by 35.17% to 2.50

August 8, 2023 | finance.yahoo.com

Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

August 7, 2023 | benzinga.com

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

August 7, 2023 | finanznachrichten.de

Amarin Corporation plc: Scottish Medicines Consortium Accepts VAZKEPA (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland

August 3, 2023 | finance.yahoo.com

Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates

August 3, 2023 | finance.yahoo.com

Amarin Reports Second Quarter 2023 Financial Results

August 2, 2023 | finanznachrichten.de

Amarin Corporation plc: Amarin Reports Second Quarter 2023 Financial Results

July 31, 2023 | finance.yahoo.com

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

July 27, 2023 | finance.yahoo.com

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

July 25, 2023 | finance.yahoo.com

Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain

See More Headlines

Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/06/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AMRN
CUSIP: N/A
CIK: 897448
Web: www.amarincorp.com
Phone: (531) 669-9020
Fax: N/A
Employees: 365
Year Founded: 1991

Price Target and Rating

Average Stock Price Target: $1.08
High Stock Price Target: $1.25
Low Stock Price Target: $1.00
Potential Upside/Downside: +44.4%
Consensus Rating: Sell
Rating Score (0-4): 1.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-105,800,000.00
Net Margins: -16.27%
Pretax Margin: -17.99%
Return on Equity: -9.12%
Return on Assets: -6.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.69
Quick Ratio: 1.74

Sales & Book Value

Annual Sales: $369.19 million
Price / Sales: 0.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.37 per share
Price / Book: 0.55

Miscellaneous

Outstanding Shares: 403,830,000
Free Float: 368,252,000
Market Cap: $302.87 million
Optionable: Optionable
Beta: 2.11

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Thomas Charles Reilly (Age 51)
Chief Financial Officer
Comp: $856.49k
Dr. Steven B. Ketchum Ph.D. (Age 58)
President of Research & Development and Chief Scientific Officer
Comp: $991.19k
Mr. Aaron D. Berg (Age 60)
Executive VP & President of U.S.
Comp: $913.7k
Mr. Patrick Holt
President, CEO & Director
Mr. Jordan Zwick (Age 36)
Senior VP of Corporate Business Development & Investor Relations
Ms. Donna Pasek
Senior Vice President of Human Resources
Mr. Laurent Abuaf
President of Europe & Senior VP
Dr. Nabil Abadir
Chief Medical Officer of Global Medical Affairs
Dr. David Keenan Ph.D.
Executive VP of Technical Operations & President of Europe

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amarin stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" AMRN shares.
View AMRN analyst ratings or view top-rated stocks.
What is Amarin's stock price target for 2024?: 3 analysts have issued 1-year price objectives for Amarin's shares. Their AMRN share price targets range from $1.00 to $1.25. On average, they predict the company's stock price to reach $1.08 in the next year. This suggests a possible upside of 44.4% from the stock's current price.
View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts.
How have AMRN shares performed in 2023?: Amarin's stock was trading at $1.21 at the beginning of 2023. Since then, AMRN shares have decreased by 38.0% and is now trading at $0.75.
View the best growth stocks for 2023 here.
When is Amarin's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our AMRN earnings forecast.
How were Amarin's earnings last quarter?: Amarin Co. plc (NASDAQ:AMRN) issued its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The biopharmaceutical company earned $66.06 million during the quarter, compared to analysts' expectations of $57.56 million. Amarin had a negative net margin of 16.27% and a negative trailing twelve-month return on equity of 9.12%.
What is John Thero's approval rating as Amarin's CEO?: 43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).
Who are Amarin's major shareholders?: Amarin's stock is owned by many different institutional and retail investors. Top institutional shareholders include Kynam Capital Management LP (2.98%), SCP Investment LP (0.74%), Stadium Capital Management LLC (0.47%), 13D Management LLC (0.37%), Axxcess Wealth Management LLC (0.32%) and UBS Group AG (0.19%). Insiders that own company stock include David M Stack, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum.
View institutional ownership trends.
How do I buy shares of Amarin?: Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Amarin have any subsidiaries?: The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More

This page (NASDAQ:AMRN) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Amarin Stock Price, News & Analysis (NASDAQ:AMRN)

Amarin MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Amarin Stock (NASDAQ:AMRN)

AMRN Stock Price History

AMRN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

AMRN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™